Verrica Pharmaceuticals Inc (NASDAQ:VRCA) has been assigned an average rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $21.67.
A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price objective on shares of Verrica Pharmaceuticals in a research report on Thursday, April 16th. BidaskClub upgraded Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine raised Verrica Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 17th. Finally, Northland Securities assumed coverage on Verrica Pharmaceuticals in a report on Wednesday. They set an “outperform” rating and a $21.00 price objective for the company.
Shares of NASDAQ VRCA opened at $14.19 on Wednesday. The company has a current ratio of 27.45, a quick ratio of 27.45 and a debt-to-equity ratio of 0.61. Verrica Pharmaceuticals has a fifty-two week low of $6.79 and a fifty-two week high of $18.67. The stock has a fifty day moving average of $11.80 and a 200-day moving average of $12.72.
Large investors have recently made changes to their positions in the company. Kornitzer Capital Management Inc. KS lifted its stake in shares of Verrica Pharmaceuticals by 5.8% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 470,274 shares of the company’s stock valued at $5,140,000 after acquiring an additional 25,743 shares during the last quarter. Geode Capital Management LLC increased its stake in Verrica Pharmaceuticals by 13.6% in the 4th quarter. Geode Capital Management LLC now owns 163,235 shares of the company’s stock worth $2,593,000 after purchasing an additional 19,510 shares during the period. State Street Corp lifted its position in Verrica Pharmaceuticals by 7.7% in the fourth quarter. State Street Corp now owns 224,524 shares of the company’s stock valued at $3,568,000 after purchasing an additional 16,098 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Verrica Pharmaceuticals in the first quarter worth approximately $167,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Verrica Pharmaceuticals in the fourth quarter worth $221,000. 34.45% of the stock is currently owned by hedge funds and other institutional investors.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.
Recommended Story: What is an inverted yield curve?
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.